[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360007-105":59,"doc-detail-360007-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-potential-antitumor-effects-of-combining-intravesical-therapy-with-recombinant-bacillus-calmette-guerin-and-an-anti-pd-1-inhibitor-in-bladder-cancer","The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guérin and an anti-PD-1 inhibitor in bladder cancer","","Recombinant Bacillus Calmette-Guérin (rBCG) and the immune checkpoint inhibitor pembrolizumab are evaluated as a combined approach for bladder cancer. The study investigates antitumor effectiveness in bladder cancer cell culture-on-a-chip models, including organoid three-dimensional systems, and confirms in vivo activity using orthotopic mouse models. Species differences are addressed by substituting a mouse PD-1 inhibitor in vivo. Results show reduced T24 viability with the combination, increased monocyte migration, and inhibited tumor growth, supporting rBCG-dltA plus PD-1 blockade as a potential strategy for BCG-unresponsive disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-potential-antitumor-effects-of-combining-intravesical-therapy-with-recombinant-bacillus-calmette-guerin-and-an-anti-pd-1-inhibitor-in-bladder-cancer/360007/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-potential-antitumor-effects-of-combining-intravesical-therapy-with-recombinant-bacillus-calmette-guerin-and-an-anti-pd-1-inhibitor-in-bladder-cancer/360007.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is rBCG and why is it used in bladder cancer treatment?","Question",{"text":112,"@type":113},"rBCG is a genetically modified form of Bacillus Calmette-Guérin designed to enhance therapeutic efficacy and safety. It aims to improve immune activation compared with conventional BCG.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the combination therapy tested in this study?",{"text":117,"@type":113},"The antitumor effects of rBCG-dltA and pembrolizumab were evaluated in a bladder cancer-on-a-chip (BCOC) model and in an orthotopic mouse model. For in vivo work, a mouse PD-1 inhibitor was used to address species differences.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings of combining rBCG-dltA with PD-1 inhibition?",{"text":121,"@type":113},"In the BCOC model, the combination reduced T24 bladder cancer cell viability and increased monocyte migration versus other groups. In the orthotopic model, combination treatment inhibited bladder cancer growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360007,1790724354,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Kim etal. BMC Cancer (2026) 26:583 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15890-x](https://doi.org/10.1186/s12885-026-15890-x)  \nRESEARCH Open Access  \nThe potential antitumor effects of combining  intravesical therapy with recombinant bacillus calmette-guérin and an anti-PD-1 inhibitor in bladder cancer  \nJung Hoon Kim 1†, Sejung Maeng2†, Joongwon Choi1, Chung Un Lee 1, Yong Seong Lee 1, Mirinae Kim2, Se Young Choi2 and In Ho Chang2*  \nAbstract  \nBackground Recombinant Bacillus Calmette-Guérin (rBCG) is a genetically modified BCG that enhances therapeutic efficacy and safety in patients with bladder cancer. Pembrolizumab is an immune checkpoint inhibitor (ICI) that is used to treat bladder cancer. We aimed to evaluate the effectiveness of the combination of rBCG and pembrolizumabin vitro and in vivo bladder cancer models.  \nMethods We investigated the antitumor effects of rBCG-dltA and pembrolizumab in a bladder cancer-on-a-chip (BCOC) model, an organoid three-dimensional cell culture tool. An orthotopic mouse model was employed to assess the in vivo effects of the combination therapy. To overcome limitations arising from differences between species, an in vivo study was conducted using a mouse PD-1 inhibitor instead of pembrolizumab.  \nResults The T24 bladder cancer cell line showed reduced viability when rBCG-dltA and pembrolizumab were used in the BCOC model. Monocyte migration was also significantly greater than that in the other groups. In the orthotopic bladder cancer model, the combination treatment inhibited the growth of bladder cancer.  \nConclusions Intravesical therapy with rBCG-dltA and pembrolizumab may be effective in treating bladder cancer. This study suggests that the combination of rBCG and ICIs may be an alternative strategy for treating patients with BCG-unresponsive bladder cancer.  \nKeywords Bacillus Calmette-Guérin, Bladder cancer, Pembrolizumab, Three-dimensional cell culture, Organ-on-achip devices  \n†Jung Hoon Kim and Sejung Maeng contributed equally to this work as co-first authors.  \n*Correspondence: In Ho Chang [caucih@cau.ac.kr](caucih@cau.ac.kr)  \n1Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Gyeonggido, Republic of Korea  \n2Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Republic of Korea  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nKim et al. BMC Cancer (2026) 26:583  \nBackground  \nAccording to Global Cancer Statistics 2020, bladder cancer is the 10th most commonly diagnosed malignant tumor in the world [1]. It is the second most common type of urinary tract cancer after prostate cancer. Although surgical management of bladder cancer has remained relatively unchanged, the field has witnessed significant advancements in therapeutic agents ","cbCaisJ6wVwcPBXs","https://ap.wps.com/l/cbCaisJ6wVwcPBXs","pdf",11698204,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Epidemiology and treatment evolution\n## Intravesical BCG therapy and limitations\n## Rationale for rBCG and combination strategies","[{\"question\":\"What is rBCG and why is it used in bladder cancer treatment?\",\"answer\":\"rBCG is a genetically modified form of Bacillus Calmette-Guérin designed to enhance therapeutic efficacy and safety. It aims to improve immune activation compared with conventional BCG.\"},{\"question\":\"How was the combination therapy tested in this study?\",\"answer\":\"The antitumor effects of rBCG-dltA and pembrolizumab were evaluated in a bladder cancer-on-a-chip (BCOC) model and in an orthotopic mouse model. For in vivo work, a mouse PD-1 inhibitor was used to address species differences.\"},{\"question\":\"What were the main findings of combining rBCG-dltA with PD-1 inhibition?\",\"answer\":\"In the BCOC model, the combination reduced T24 bladder cancer cell viability and increased monocyte migration versus other groups. In the orthotopic model, combination treatment inhibited bladder cancer growth.\"}]","The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guérin and an anti-PD-1 inhibitor in bladder cancer | PDF",1790138487,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c32bef012c2883524adfa79061542685.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9853dc1a32e10c5f0a93a5f768300fff.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d48c3e8d93021f58b66cc51d4c788c8f.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7744a79d1adfbc579a693699aad875ea.webp",980,1306]